MDS Virtual Congress 2021 Archives - Page 127 of 132

Lack of diversity in Parkinson’s disease genetic research: current landscape and future directions

A. Schumacher-Schuh, A. Bieger, M. Strelow, O. Okunoye, K. Mok, A. Ahmad-Annuar, S. Bardien, S-Y. Lim, S. Rao, Y. Zewde, S. Dindayal, J. Azar, S. Lesage, I. Mata, GP2. Genetics Project (Porto Alegre, Brazil)
Lance-Adams Syndrome: A case series in El Salvador

J. Lopez-Castellanos, J. Lopez-Contreras (Little Rock, USA)
Language impairment in Corticobasal Syndrome: from clinical phenotype to biomarkers

J. Parmera, M. Oliveira, A. Coutinho, I. de Almeida, C. Carneiro, A. Neto, R. Nitrini, C. Buchpiguel, E. Barbosa, S. Brucki (São Paulo, Brazil)
Laryngeal Electromyography Findings in patients with Multiple System Atrophy

F. Gandor, A. Vogel, A. Haghikia, G. Ebersbach, T. Warnecke, D. Gruber (Beelitz-Heilstätten, Germany)
Late-onset chorea in the setting of cerebrovascular disease

C. Selvadurai, A. Patel (New Haven, USA)
Late-onset Familial Segmental Dystonia with Novel GNAL Mutation

B. Barton, J. Karl, L. Verhagen, M. Rosenbaum (Chicago, USA)
Lateralization of cochlear dysfunction as a specific biomarker of Parkinson’s disease; role for cholinergic transmission?

R. Cerroni, A. Viziano, A. Stefani, R. Sisto (Rome, Italy)
Lateralized Tau Pathology in a Case of Lewy Body Dementia with Corticobasal Syndrome

D. Coughlin, H. Coslett, C. Mcmillan, J. Phillips, E. Lee, J. Trojanowski, M. Grossman, D. Irwin (San Diego, USA)
Leg muscle contractions compensate for declining cardiac baroreflex in PD Patients

A. Huether, R. Fadil, R. Brunnemer, T. Harlow, A. Stutz, S. Matcha, A. Hanson, A. Blaber, K. Tavakolian, J-S. Lou (Fargo, USA)
Levodopa responsive gait dynamics in ON- and OFF-state freezing of gait in Parkinson’s disease

T. Virmani, L. Pillai, A. Glover, R. Landes (Little Rock, USA)
Levodopa-Carbidopa Intestinal Gel Therapy for Advanced Parkinson’s Disease: A Single Center ‘Real World’ Study of Patients with and without DBS

P. Dole, S. Green, M. Wiggins, J. Joseph, M. Gaspari, M. Siddiqui (Winston-Salem, USA)
Levodopa/carbidopa intestinal gel (LCIG) reduces fluctuations and shortens time to on without troublesome dyskinesia in advanced Parkinson’s Disease: Post-hoc analyses of 54-week LCIG-monotherapy trial

R. Pahwa, J. Aldred, A. Merola, N. Gupta, E. Terasawa, V. Garcia-Horton, P. Kandukuri, Y. Jalundhwala, Y. Bao, O. Ladhani, S. Isaacson (Kansas City, USA)
LFP spectral features associated with therapy complications in typical and early onset Parkinson’s disease

E. Belova, U. Semenova, A. Gamaleya, A. Tomskiy, A. Sedov (Moscow, Russian Federation)
Life Satisfaction and Adaptation in Persons with Parkinson’s Disease

L. Rosengren, A. Forsberg, C. Brogardh, J. Lexell (Lund, Sweden)
Limitations of conventional dopaminergic medication in advanced Parkinson’s disease: results from 127 patients treated with Levodopa Carbidopa Intestinal Gel

J. Szász, V. Constantin, K. Orban-Kiss, L. Bancu, D. Georgescu, J. Szederjesi, M. Ciorba, A. Racz, I. Mihaly, K. Kelemen, S. Szatmari (Targu Mures, Romania)
Lingual myoclonus associated with brain metastasis located near the primary tongue motor cortex: case report.

G. Velilla Alonso, J. Soto Alsar, JJ. Rodríguez Irausquin, A. Sánchez Soblechero (Madrid, Spain)
Links between Cognitive Impairment and Contrast Sensitivity in Parkinson’s Disease

C. Catiul, R. Memon, A. Memon, A. Joop, J. Pilkington, K. Wood, A. Amara (Birmingham, USA)
LIPAD (LRRK2/Luebeck) International Parkinson’s Disease Study: Protocol and feasibility study

T. Usnich, EJ. Vollstedt, N. Schell, V. Skrahina, X. Bogdanovic, H. Gaber, T. Förster, A. Heuer, N. Koleva-Alazeh, I. Csoti, A. Nazli Basak, S. Ertan, G. Genc, P. Bauer, K. Lohmann, A. Grünewald, E. Schymanski, J. Trinh, S. Schaake, D. Berg, D. Gruber, S. Isaacson, A. Kühn, B. Mollenhauer, D. Pedrosa, K. Reetz, E. Sammler, EM. Valente, F. Valzania, J. Volkmann, S. Zittel, N. Brüggemann, M. Kasten, A. Rolfs, C. Klein (Lübeck, Germany)
Lipid metabolism alterations in the lysosomal membrane promotes chaperone-mediated autophagy dysfunction and alpha-synuclein pathology in Parkinson’s disease associated to GBA

A. Navarro-Romero, I. Fernandez-Gonzalez, M. Montpeyo, J. Riera, E. Pradas, JA. Arranz, C. Carnicer-Caceres, M. Martinez-Vicente (Barcelona, Spain)
Living with dystonia during first-wave of COVID-19 pandemic: a Framework Analysis of Open-Ended Survey Questions

S. Coniglio, G. Di Rauso, V. Rispoli, M E. Díaz Crescitelli, F. Cavallieri, F. Antonelli, S. Meletti, L. Ghirotto, F. Valzania (Modena, Italy)
Local Field Potentials (LFP) used to guide treatment of biphasic dyskinesias in a patient with Parkinson’s Disease (PD)

O. Vaou, C. Harrington, S. Stanslaski, R. Cosgrove, A. Depold Hohler (Brighton, USA)
Locus coeruleus degeneration associated with less levodopa responsiveness in Parkinson’s Disease

C. Zhou, B. Zhang, M. Zhang (Hangzhou, China)
Locus coeruleus volume is reduced in Parkinson disease-related orthostatic hypotension.

P. Beach, N. Kurra, K. Hwang, J. Langley, X. Hu, D. Huddleston (Atlanta, USA)
Long term follow-up of Wilson disease patients in Poland. Report from the national reference centre.

A. Członkowska, T. Litwin, ł. Kraiński, M. Skowrońska, A. Piechal, A. Antos, M. Niewada (Warszawa, Poland)
Long-term clinical outcome of deep brain stimulation in pantothenate kinase-associated neurodegeneration: a retrospective observational study

KA. Woo, HJ. Kim, SJ. Chung, J. Youn, JH. Ahn (Seoul, Republic of Korea)
Long-term cognitive and motor decline across the spectrum of Lewy body disease.

MC. Gonzalez, J. Maple-Grødem, D. Tovar‐rios, CH. Williams-Gray, M. Camacho, L. Forsgren, D. Bäckström, R. Lawson, AD. Macleod, CE. Counsell, C. Paquet, C. Falup-Pecurariu, F. Blanc, A. Padovani, C. de Lena, F. D'Antonio, G. Alves, D. Aarsland (Stavanger, Norway)
Long-term effect of safinamide on primary motor cortex excitability and plasticity in Parkinson’s disease: a TMS study

V. D'Onofrio, A. Guerra, F. Asci, G. Fabbrini, A. Berardelli, A. Suppa (Rome, Italy)
Long-Term Evaluation of Deep Brain Stimulation for Treatment of Parkinson’s Disease Using a Multiple-Source, Constant-Current Rechargeable System: 4-year Follow-Up of a Prospective, Double-Blind RCT

J. Vitek, R. Jain, L. Chen, A. Tröster, L. Schrock, P. House, M. Giroux, A. Hebb, S. Farris, D. Whiting, T. Lechleiter, J. Ostrem, M. San Luciano, N. Galifianakis, L. Verhagen Metman, S. Sani, J. Karl, M. Siddiqui, S. Tatter, I. Ul Haq, A. Machado, M. Gostkowski, M. Tagliati, A. Mamelak, M. Okun, K. Foote, G. Moguel-Cobos, F. Ponce, R. Pahwa, J. Nazarro, C. Buetefisch, R. Gross, C. Luca, J. Jagid, G. Revuelta, I. Takacs, M. Pourfar, A. Mogilner, A. Duker, G. Mandybur, J. Rosenow, S. Cooper, M. Park, S. Khandhar, M. Sedrak, F. Phibbs, J. Pilitsis, R. Uitti, P. Starr (Minneapolis, USA)
Long-Term Motor Function and Quality of Life Outcomes from a Prospective, International DBS Registry

G. Deuschl, R. Jain, J. Wang, M. Barbe, S. Paschen, C. Sik Lee, J. Volkmann, A. Kühn, J. Vesper (Kiel, Germany)
Long-term real-world effectiveness of carbidopa/levodopa enteral suspension after 36 months of treatment initiation: Final results from PROviDE study

R. Pahwa, S. Isaacson, R. Dorsey, D. Cella, B. Bluett, S. Thakkar, P. Kandukuri, N. Gupta, Y. Jalundhwala, Y. Bao, I. Pan, O. Ladhani, J. Aldred (Kansas City, USA)
Long-term safety and activity of ecopipam (ECO), a selective D1 antagonist during treatment of pediatric patients with Tourette Syndrome

R. Chipkin, A. Mahableshwarkar, D. Gilbert (Chicago, USA)
Long-Term Safety and Efficacy of Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease

S. Factor, W. Ondo, S. Isaacson, I. Zhang, E. Pappert, B. Navia (Atlanta, USA)
Long-Term Safety and Efficacy of Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Europe vs North America

R. Pahwa, S. Fox, J. Hui, C. Singer, J. Schwarz, M F. de Pandis, J. Raw, I. Zhang, E. Pappert, B. Navia (Kansas City, USA)
Longitudinal 18F-PBR06 (TSPO) and Volumetric MR Imaging as Pharmacodynamic Endpoints for MSA – Ongoing Investigator Sponsored Trial of Verdiperstat

T. Singhal, A. Pitaro, J. Kim, J. Woods, M. Mesidor, J. Ficke, A. Willett, S. Cicero, K. O'Connor, I. Qureshi, G. Young, V. Khurana (Boston, USA)
Longitudinal change in thalamic white matter macrostructure and volume in Parkinson’s disease depression

R. Bhome, A. Zarkali, J. Cole, R. Weil (London, United Kingdom)
Longitudinal changes in nigral neuromelanin in early, levodopa-treated Parkinson’s disease

K. Hwang, J. Langley, N. Kurra, S. Factor, X. Hu, D. Huddleston (Atlanta, USA)
Longitudinal changes of gait parameters in early Parkinson’s disease

V. Marković, I. Stanković, S. Radovanović, I. Petrović, T. Stojković, V. Kostić (Belgrade, Serbia)
Longitudinal healthcare utilization and costs in Parkinson disease : from pre-diagnosis to 9 years

S. Neo, E. Soh, A. Wong, W. Li, HL. Ng, KY. Tay, WL. Au, L. Tan (Singapore, Singapore)
Longitudinal Speech Changes In PD and the Relationship to Limb Bradykinesia and Rigidity

R. Richter, S. Gutierrez, R. Bennett, C. Deckelman, F. Docters, A. Lang, D. Breen, C. Marras, M. Masellis, D. Grimes, M. Jog, B. Tan, K. Sunderland, JB. Orange, P. Mclaughlin, A. Troyer, B. Levine, D. Beaton, M. Binns, D. Munoz, R. Swartz, A. Roberts (Evanston, USA)
Longitudinal structural and functional brain alterations in Parkinson’s disease patients with freezing of gait

N. Piramide, F. Agosta, E. Sarasso, T. Stojkovic, I. Stankovic, S. Basaia, A. Tomic, V. Markovic, E. Stefanova, V. Kostic, M. Filippi (Milan, Italy)
Longitudinal Study of Grey Matter Nuclei in Early Parkinson’s Disease using Diffusion Kurtosis Imaging

T. Welton, S. Hartono, Y-C. Shih, W. Lee, SL. Chong, S. Ng, N. Chia, EK. Tan, LL. Chan, L. Tan (Singapore, Singapore)
LOSS OF SPIRAL AXIS FOR DIAGNOSES OF FUNCTIONAL TREMOR

F. Alonso-Frech, V. Gomez-Mayordomo, A. Baltasar-Corral, M. Hernández-García, R. García-Ramos, E. Lopez-Valdes, A. Fernandez-Revuelta (Madrid, Spain)
Low dose trihexyphenidyl use causes cognitive dysfunction in Parkinson’s disease patients.

L. Popil, M. Gavriliuc, A. Andrusca, O. Gavriliuc (Chisinau, Republic of Moldova)
Low Frequency Oscillations at Limbic GPi during pre-tic activity seems associated with premonitory urges in Tourette Syndrome

M. Wilken, D. Cerquetti, M. Rossi, J. Obeso, M. Merello (Buenos Aires, Argentina)
LRRK2 Inhibition by BIIB122 / DNL151: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Ph 1 Healthy Volunteer and Ph 1B Parkinson’s Disease Trials

D. Jennings, J. Wetering Derooij, M. Vissers, J. Heuberger, G. Groeneveld, R. Macuica, A. Kay, M. Borin, B. Wong, V. Daryani, S. Huntwork-Rodriguez, P. Chin, C. Ho, M. Troyer (South San Francisco, USA)
LY-487,379 alleviates parkinsonism when administered as monotherapy in the MPTP-lesioned marmoset

I. Frouni, C. Kwan, S. Nuara, S. Belliveau, A. Hamadjida, W. Kang, D. Bédard, J. Gourdon, P. Huot (Montreal, Canada)
LY-487,379 enhances the anti-parkinsonian action of a low dose of L-DOPA in the MPTP-lesioned marmoset

C. Kwan, I. Frouni, S. Nuara, S. Belliveau, A. Hamadjida, W. Kang, D. Bédard, J. Gourdon, P. Huot (Montreal, Canada)
Lysosomal storage disorder genes variants in Parkinson’s disease: a large cohort study in Chinese mainland population

Y. Zhao, H. Pan, Y. Wang, Z. Liu, Q. Zeng, Z. Fang, K. Xu, Z. Wang, X. Zhou, R. He, B. Li, G. Zhao, Q. Xu, Q. Sun, X. Yan, J. Tan, J. Li, J. Guo, B. Tang (Changsha, China)